Research Watch: Headlines Worth Watching — September 8, 2026

Longevity & Aging: Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment.

Why it matters: Relevant to I-OM domains of Longevity & Healthy Aging, specifically intersecting with root drivers of metabolic dysfunction and major biological processes of cellular senescence, chronic inflammation, and impaired repair. The study provides a novel methodological framework for assessing these processes via proteomic biomarkers in human trials. Supports the conceptual feasibility of integrating proteomic aging endpoints into disease-specific clinical trials to simultaneously assess geroprotective potential.

What the evidence actually shows: Six proteomic aging clocks (ProtAge, OrganAgemortality, OrganAgechrono, PAC, ipfP3GPT, PAOPAC) consistently predicted lower biological age in rentosertib-treated arms versus controls in a 12-week phase 2a IPF trial.

What we don’t know yet: Secondary analysis of a previously published phase 2a trial; sample size and statistical power for aging endpoints are likely limited by the original trial design.

Research Watch verdict: Early


Emerging Cancer Technology: A first-in-human, prospective feasibility trial of a next-generation, shear-responsive, liquid embolic biomaterial, NeoCast.

Why it matters: Minimal to none. This is a neurointerventional surgical device study unrelated to I-OM’s focus on nutritional, metabolic, environmental, or systems-based root drivers of disease. The procedural use of microvascular occlusion does not relate to I-OM’s concept of pathological microvascular dysfunction. Results support continued clinical investigation of NeoCast for pre-surgical embolization but are insufficient to change current neurointerventional practice due to the small feasibility-stage sample size.

What the evidence actually shows: NeoCast achieved complete occlusion in all targeted vessels across all 5 enrolled subjects.

What we don’t know yet: Extremely small sample size (n=5), limiting generalizability and statistical power.

Research Watch verdict: Promising


Want the important health research without the noise? Follow I-OM Research Watch for daily evidence updates.